Furthermore, compared to unmodified TLR agonists, the sustained release nature of TransCon TLR7/8 Agonist may allow for greater patient access by facilitating less frequent treatment visits thus making intratumoral delivery more practical not only for more accessible tumors (e.g., melanoma and head and neck) but also for deeper tumors (e.g., lung). This evidence concerns the gene TLR7 and melanoma.